11,000 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Acquired by Triglav Skladi D.O.O.

Triglav Skladi D.O.O. purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,000 shares of the biotechnology company's stock, valued at approximately $1,337,000.

Other hedge funds have also recently modified their holdings of the company. Louisiana State Employees Retirement System increased its position in Sarepta Therapeutics by 0.4% during the fourth quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company's stock valued at $3,222,000 after acquiring an additional 100 shares during the last quarter. EP Wealth Advisors LLC increased its position in Sarepta Therapeutics by 2.2% during the fourth quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock valued at $606,000 after acquiring an additional 105 shares during the last quarter. Manchester Capital Management LLC increased its position in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 110 shares during the last quarter. UMB Bank n.a. increased its position in Sarepta Therapeutics by 36.0% during the fourth quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company's stock valued at $63,000 after acquiring an additional 138 shares during the last quarter. Finally, CIBC Asset Management Inc increased its position in Sarepta Therapeutics by 5.1% during the fourth quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company's stock valued at $347,000 after acquiring an additional 139 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. This represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 7.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have issued reports on SRPT shares. Oppenheimer cut their price target on Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Scotiabank cut their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a report on Thursday, March 20th. The Goldman Sachs Group cut their price target on Sarepta Therapeutics from $178.00 to $100.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. HC Wainwright cut their price target on Sarepta Therapeutics from $75.00 to $40.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Finally, Evercore ISI lowered Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 price objective for the company. in a research note on Thursday, May 8th. Six research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $122.61.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock traded up $0.06 during trading hours on Wednesday, hitting $40.05. 8,428,037 shares of the company were exchanged, compared to its average volume of 1,767,439. Sarepta Therapeutics, Inc. has a 1 year low of $34.10 and a 1 year high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The business has a 50-day moving average of $56.56 and a 200-day moving average of $95.81. The stock has a market capitalization of $3.94 billion, a price-to-earnings ratio of 32.04 and a beta of 0.85.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The company had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. During the same quarter last year, the company earned $0.73 EPS. Sarepta Therapeutics's revenue for the quarter was up 80.2% compared to the same quarter last year. As a group, analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.